Atlas Trials

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Clinical trial NCT04409288 · TERMINATED

Trial details

NCT number
NCT04409288
Sponsor
Chinese University of Hong Kong
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Prostate Cancer
Start date
2020-07-20
Primary completion
2023-10-16
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.